CRISPR Therapeutics AG
http://www.crisprtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CRISPR Therapeutics AG
BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions
An upfront payment of $110m from BMS has come just in time for Prime Medicine, but its real test will be the first Phase I data, expected early next year.
Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited
The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.
Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited
The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.
Gene Therapy Patient Pipeline Builds, But Slowly, In Q2
Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Casebia Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice